Trials / Recruiting
RecruitingNCT07108036
A Study to Assess Anktiva in Patients With Long Covid-19.
Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- ImmunityBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-803 (IL-15 Superagonist) | N-803 administered subcutaneously. |
Timeline
- Start date
- 2025-11-14
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2025-08-06
- Last updated
- 2026-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07108036. Inclusion in this directory is not an endorsement.